# Addition of Azathioprine in IBD Patients With Immunogenic Failure

> **NCT03580876** · PHASE4 · UNKNOWN · sponsor: **Védrines, Philippe, M.D.** · enrollment: 90 (estimated)

## Conditions studied

- Clinical Failure After Switch

## Interventions

- **DRUG:** addition of azathioprine
- **DRUG:** Switch to a second anti-TNF drug alone

## Key facts

- **NCT ID:** NCT03580876
- **Lead sponsor:** Védrines, Philippe, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-23
- **Primary completion:** 2019-06-10
- **Final completion:** 2020-06-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580876, "Addition of Azathioprine in IBD Patients With Immunogenic Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03580876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*